Paolo Cassano, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 27 | 2024 | 4810 | 2.990 |
Why?
|
| Infrared Rays | 6 | 2023 | 246 | 2.640 |
Why?
|
| Photochemotherapy | 2 | 2019 | 828 | 0.840 |
Why?
|
| Skull | 4 | 2019 | 819 | 0.840 |
Why?
|
| Neuralgia | 2 | 2024 | 618 | 0.710 |
Why?
|
| Brain | 12 | 2024 | 27159 | 0.680 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2018 | 193 | 0.540 |
Why?
|
| Lithium | 1 | 2019 | 599 | 0.530 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2018 | 125 | 0.530 |
Why?
|
| Phototherapy | 1 | 2019 | 368 | 0.530 |
Why?
|
| Antimanic Agents | 1 | 2019 | 523 | 0.500 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2006 | 490 | 0.490 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2024 | 1495 | 0.470 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 880 | 0.450 |
Why?
|
| Cerebrovascular Circulation | 2 | 2021 | 2672 | 0.440 |
Why?
|
| Anxiety Disorders | 4 | 2019 | 2744 | 0.430 |
Why?
|
| Dopamine Agonists | 3 | 2005 | 346 | 0.430 |
Why?
|
| Antidepressive Agents | 9 | 2024 | 2903 | 0.410 |
Why?
|
| Comorbidity | 8 | 2024 | 10580 | 0.400 |
Why?
|
| Double-Blind Method | 9 | 2024 | 12430 | 0.390 |
Why?
|
| Down Syndrome | 1 | 2019 | 916 | 0.360 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1089 | 0.360 |
Why?
|
| Fluoxetine | 2 | 2005 | 732 | 0.350 |
Why?
|
| Brain Diseases | 1 | 2019 | 1552 | 0.350 |
Why?
|
| Hallucinations | 1 | 2013 | 373 | 0.340 |
Why?
|
| Psychotic Disorders | 3 | 2015 | 3276 | 0.340 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2009 | 34 | 0.330 |
Why?
|
| Body Weight | 1 | 2019 | 4626 | 0.310 |
Why?
|
| Drug Resistance | 2 | 2005 | 1592 | 0.300 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 1463 | 0.300 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 276 | 0.300 |
Why?
|
| Sampling Studies | 2 | 2019 | 614 | 0.300 |
Why?
|
| Electroencephalography | 2 | 2021 | 6282 | 0.300 |
Why?
|
| Mood Disorders | 2 | 2024 | 1127 | 0.280 |
Why?
|
| Cognition | 3 | 2024 | 7057 | 0.270 |
Why?
|
| Cytokines | 2 | 2024 | 7438 | 0.270 |
Why?
|
| Depression | 8 | 2023 | 8228 | 0.260 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 8717 | 0.250 |
Why?
|
| Treatment Outcome | 17 | 2024 | 65273 | 0.240 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2024 | 877 | 0.230 |
Why?
|
| Humans | 59 | 2024 | 766766 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2024 | 606 | 0.220 |
Why?
|
| Pilot Projects | 4 | 2021 | 8728 | 0.220 |
Why?
|
| Depressive Disorder | 5 | 2018 | 3715 | 0.220 |
Why?
|
| Anxiety | 1 | 2018 | 4670 | 0.210 |
Why?
|
| Euphoria | 1 | 2022 | 64 | 0.200 |
Why?
|
| Female | 40 | 2024 | 396520 | 0.200 |
Why?
|
| Adult | 34 | 2024 | 223307 | 0.200 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 5130 | 0.200 |
Why?
|
| Male | 38 | 2024 | 364142 | 0.190 |
Why?
|
| Inflammation | 2 | 2024 | 10860 | 0.190 |
Why?
|
| Ketamine | 2 | 2017 | 527 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2020 | 6869 | 0.170 |
Why?
|
| Yoga | 1 | 2023 | 277 | 0.170 |
Why?
|
| Lasers, Semiconductor | 1 | 2019 | 44 | 0.160 |
Why?
|
| Hypertension | 1 | 2019 | 8616 | 0.160 |
Why?
|
| Thiazoles | 2 | 2004 | 1529 | 0.160 |
Why?
|
| Spectrum Analysis | 1 | 2021 | 443 | 0.160 |
Why?
|
| Young Adult | 9 | 2024 | 59939 | 0.160 |
Why?
|
| Middle Aged | 27 | 2024 | 223257 | 0.150 |
Why?
|
| Ubiquinone | 1 | 2018 | 181 | 0.140 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 39309 | 0.140 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 183 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15908 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1587 | 0.140 |
Why?
|
| Indoles | 1 | 2005 | 1834 | 0.140 |
Why?
|
| Maze Learning | 1 | 2018 | 479 | 0.140 |
Why?
|
| Nose | 1 | 2020 | 522 | 0.130 |
Why?
|
| Stress, Psychological | 2 | 2024 | 4527 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 646 | 0.130 |
Why?
|
| Prefrontal Cortex | 3 | 2022 | 2224 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 658 | 0.120 |
Why?
|
| Hospitals, General | 1 | 2019 | 804 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2018 | 303 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2012 | 1988 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2019 | 3432 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3139 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2846 | 0.110 |
Why?
|
| Psychotherapy | 1 | 2023 | 1648 | 0.110 |
Why?
|
| Universities | 1 | 2018 | 1004 | 0.110 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2005 | 250 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4349 | 0.100 |
Why?
|
| Body Constitution | 1 | 1992 | 273 | 0.100 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 1498 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4913 | 0.100 |
Why?
|
| Telomere | 1 | 2018 | 943 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2019 | 2764 | 0.090 |
Why?
|
| Aged | 16 | 2024 | 171343 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 5 | 2024 | 6020 | 0.090 |
Why?
|
| Adolescent | 10 | 2019 | 88904 | 0.090 |
Why?
|
| Cyclohexanols | 3 | 2006 | 126 | 0.090 |
Why?
|
| Acculturation | 1 | 2012 | 179 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2936 | 0.090 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3078 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 7119 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2019 | 41710 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 16044 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 10619 | 0.080 |
Why?
|
| Testosterone | 1 | 2020 | 2495 | 0.080 |
Why?
|
| Public Health | 1 | 2002 | 2681 | 0.080 |
Why?
|
| Citalopram | 3 | 2006 | 402 | 0.080 |
Why?
|
| Hippocampus | 2 | 2018 | 3776 | 0.080 |
Why?
|
| Language | 1 | 2018 | 1550 | 0.080 |
Why?
|
| Students | 1 | 2018 | 1741 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6307 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2018 | 2645 | 0.070 |
Why?
|
| Rural Population | 1 | 1998 | 2321 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 18075 | 0.070 |
Why?
|
| Cognition Disorders | 3 | 2007 | 3967 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 18397 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2758 | 0.070 |
Why?
|
| Boston | 1 | 2019 | 9346 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 4853 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2015 | 22248 | 0.060 |
Why?
|
| Suicidal Ideation | 1 | 2016 | 1467 | 0.060 |
Why?
|
| Vasomotor System | 1 | 2006 | 208 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2002 | 4735 | 0.060 |
Why?
|
| Benzothiazoles | 2 | 2004 | 244 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 6222 | 0.060 |
Why?
|
| Mitochondria | 1 | 2018 | 3677 | 0.060 |
Why?
|
| Motor Skills Disorders | 1 | 2005 | 89 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4249 | 0.060 |
Why?
|
| Anger | 1 | 2007 | 402 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2005 | 427 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2018 | 1193 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3850 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2013 | 2021 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2019 | 54871 | 0.060 |
Why?
|
| Premenstrual Syndrome | 1 | 2004 | 111 | 0.060 |
Why?
|
| Valine | 1 | 2005 | 410 | 0.050 |
Why?
|
| Moclobemide | 1 | 2003 | 4 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 4628 | 0.050 |
Why?
|
| Schizophrenia | 3 | 2007 | 6976 | 0.050 |
Why?
|
| Methionine | 1 | 2005 | 569 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3624 | 0.050 |
Why?
|
| Paroxetine | 1 | 2003 | 181 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 40149 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21162 | 0.050 |
Why?
|
| Time | 1 | 2004 | 550 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2228 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 1993 | 3314 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10384 | 0.050 |
Why?
|
| Body Temperature | 1 | 2024 | 780 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 10745 | 0.040 |
Why?
|
| Aging | 2 | 2018 | 8731 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 364 | 0.040 |
Why?
|
| Lung | 1 | 1998 | 10067 | 0.040 |
Why?
|
| Animals | 6 | 2024 | 168930 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2009 | 9661 | 0.040 |
Why?
|
| Nurses | 1 | 2009 | 2503 | 0.040 |
Why?
|
| Losartan | 1 | 2021 | 263 | 0.040 |
Why?
|
| Genotype | 3 | 2009 | 13036 | 0.040 |
Why?
|
| Postmenopause | 2 | 2006 | 2517 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2006 | 4421 | 0.040 |
Why?
|
| Gyrus Cinguli | 2 | 2020 | 1118 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 29948 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 12985 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 24295 | 0.040 |
Why?
|
| Pregnancy | 1 | 2019 | 30237 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 36567 | 0.040 |
Why?
|
| Rural Health | 1 | 1998 | 302 | 0.030 |
Why?
|
| Fatigue | 1 | 2004 | 1555 | 0.030 |
Why?
|
| Neuroimmunomodulation | 1 | 2018 | 186 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 789 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2004 | 6329 | 0.030 |
Why?
|
| Prevalence | 1 | 2012 | 15835 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2024 | 3681 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 1065 | 0.030 |
Why?
|
| Sertraline | 2 | 2006 | 210 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1980 | 0.030 |
Why?
|
| Bupropion | 2 | 2006 | 303 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 1998 | 1691 | 0.030 |
Why?
|
| Risk Factors | 4 | 2009 | 74881 | 0.030 |
Why?
|
| Rabbits | 1 | 2019 | 4752 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 2429 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7241 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 2121 | 0.030 |
Why?
|
| United States | 3 | 2018 | 72951 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2006 | 1019 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1756 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 13476 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 2505 | 0.020 |
Why?
|
| China | 1 | 1998 | 2383 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1838 | 0.020 |
Why?
|
| Hip | 1 | 1992 | 251 | 0.020 |
Why?
|
| Obesity | 2 | 1993 | 13090 | 0.020 |
Why?
|
| Child | 1 | 2019 | 80668 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2018 | 1865 | 0.020 |
Why?
|
| Antioxidants | 1 | 2018 | 1671 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 81635 | 0.020 |
Why?
|
| Sleep | 1 | 2006 | 4815 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 2413 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2035 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2817 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 3724 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1992 | 12245 | 0.020 |
Why?
|
| Linear Models | 1 | 1998 | 5874 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 8106 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 81889 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9357 | 0.020 |
Why?
|
| Norethindrone | 1 | 2006 | 52 | 0.020 |
Why?
|
| Abdomen | 1 | 1992 | 1137 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 3060 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2006 | 111 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2006 | 300 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1993 | 2001 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1993 | 1806 | 0.020 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2005 | 18 | 0.020 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2005 | 36 | 0.020 |
Why?
|
| Perimenopause | 1 | 2006 | 142 | 0.020 |
Why?
|
| Body Mass Index | 2 | 1993 | 13050 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2005 | 152 | 0.010 |
Why?
|
| Buspirone | 1 | 2005 | 80 | 0.010 |
Why?
|
| Retreatment | 1 | 2006 | 598 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 146 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2007 | 550 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14652 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2004 | 138 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5887 | 0.010 |
Why?
|
| Body Composition | 1 | 1993 | 2441 | 0.010 |
Why?
|
| Hot Flashes | 1 | 2006 | 329 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 1001 | 0.010 |
Why?
|
| Rats | 1 | 2019 | 23717 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2005 | 646 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9513 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8540 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2005 | 898 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6214 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 255 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 22352 | 0.010 |
Why?
|
| Diet | 1 | 1998 | 8088 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 1479 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2007 | 1716 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2921 | 0.010 |
Why?
|
| Estrogens | 1 | 2006 | 1528 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 36461 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2005 | 2342 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18330 | 0.010 |
Why?
|
| Insulin | 1 | 1993 | 6608 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2005 | 1647 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4570 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 6422 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1992 | 12534 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 26310 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 2002 | 505 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4114 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2005 | 1413 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2003 | 59550 | 0.010 |
Why?
|
| Suicide | 1 | 2006 | 1606 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 21525 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 2779 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 6895 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 9602 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13278 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 4400 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1993 | 667 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12791 | 0.010 |
Why?
|
| Anthropometry | 1 | 1993 | 1336 | 0.000 |
Why?
|
| Fasting | 1 | 1993 | 1609 | 0.000 |
Why?
|
| Smoking | 1 | 1993 | 9077 | 0.000 |
Why?
|